RASSF1A, which also exhibits tumor suppressor properties in soft tissue and bone tissue cancers, has been shown to be low expressed in osteosarcoma, and low expression is associated with a poor clinical course [63]. This evidence concerns the gene RASSF1 and osteosarcoma.